Table 5.
Odds ratios for postmenopausal breast cancer by haplotypes in the vitamin D receptorgene under the log-additive model
| Haplotypea | Haplotype frequencies (%) | OR (95% CI) | ||||
| Cases (n = 1,408) | Controls (n = 2,612) | Crude modelb | Adjusted modelc | |||
| FTCG | 0.178 | 0.183 | 1 | 1 | ||
| FTCA | 0.036 | 0.049 | 0.76 | (0.51–1.15) | 0.81 | (0.53–1.23) |
| FTTG | 0.124 | 0.116 | 1.12 | (0.87–1.43) | 1.09 | (0.84–1.40) |
| FTTA | 0.025 | 0.025 | 1.10 | (0.69–1.77) | 1.16 | (0.71–1.88) |
| FtCG | 0.117 | 0.113 | 1.07 | (0.83–1.38) | 1.06 | (0.82–1.39) |
| FtCA | 0.052 | 0.035 | 1.50 | (1.07–2.12) | 1.43 | (1.00–2.05) |
| FtTG | 0.076 | 0.079 | 0.98 | (0.76–1.27) | 1.04 | (0.80–1.36) |
| FtTA | 0.016 | 0.015 | 1.05 | (0.59–1.87) | 0.98 | (0.54–1.79) |
| fTCG | 0.109 | 0.117 | 0.97 | (0.75–1.24) | 0.97 | (0.75–1.26) |
| fTCA | 0.028 | 0.023 | 1.19 | (0.72–1.96) | 1.17 | (0.70–1.95) |
| fTTG | 0.080 | 0.083 | 0.98 | (0.75–1.26) | 1.04 | (0.80–1.35) |
| fTTA | 0.011 | 0.011 | 1.07 | (0.48–2.37) | 0.93 | (0.41–2.09) |
| ftCG | 0.048 | 0.041 | 1.19 | (0.84–1.69) | 1.19 | (0.82–1.72) |
| ftCA | 0.024 | 0.027 | 0.94 | (0.57–1.55) | 0.95 | (0.56–1.64) |
| ftTG | 0.065 | 0.072 | 0.94 | (0.71–1.25) | 0.94 | (0.70–1.27) |
aFokI, TaqI, VDR-5132, Cdx2 (with > 1% frequency in the study population). bUnconditional haplotype analysis adjusted for matching factor year of birth. cUnconditional haplotype analysis adjusted for year of birth, age at menopause, first-degree family history of breast cancer, history of benign breast disease, number of pregnancies (≥28th week), age at menarche, breastfeeding history, total number of mammograms, use of hormone therapy, body mass index, education level and smoking status. CI, confidence interval; OR, odds ratio.